Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

  • Ayala, Rosa|||0000-0002-2699-8353
  • Rapado, Inmaculada
  • Onecha, Esther
  • Martínez-Cuadrón, David|||0000-0001-7540-4091
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Algarra Algarra, Jesus Lorenzo
  • Tormo, Mar|||0000-0001-9622-1649
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Serrano, Josefina
  • Herrera, Pilar|||0000-0002-4118-7110
  • Ramos, Fernando
  • Salamero, Olga|||0000-0003-3237-0025
  • Lavilla, Esperanza|||0000-0003-1490-0678
  • Gil, Cristina
  • López Lorenzo, José L.|||0000-0003-1502-3902
  • Vidriales, María Belén|||0000-0001-5049-3673
  • Labrador, Jorge|||0000-0002-3696-0287
  • Falantes, José Francisco|||0000-0001-8660-7038
  • Sayas, María José
  • Paiva, Bruno|||0000-0003-1977-3815
  • Barragán, Eva
  • Prosper, Felipe|||0000-0001-6115-8790
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Montesinos, Pau|||0000-0002-3275-5593
Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10 -7) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT02319135.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

  • Onecha, Esther
  • Linares, Maria
  • Rapado, Inmaculada
  • Ruiz-Heredia, Yanira
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Cedena, Teresa
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Oteyza, Jaime Perez
  • Herrera, Pilar|||0000-0002-4118-7110
  • Barragán, Eva
  • Montesinos, Pau|||0000-0002-3275-5593
  • Vela, Jose Antonio Garcia
  • Magro, Elena
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Figuera, Angela
  • Riaza, Rosalia
  • Martinez-Barranco, Pilar
  • Sanchez-Vega, Beatriz
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Miguel
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ayala, Rosa|||0000-0002-2699-8353
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing method achieved a sensitivity of 10 for single nucleotide variants and 10 for insertions/deletions and could be used in acute myeloid leukemia patients who carry any mutation (86% in our diagnostic data set). Sequencing-determined minimal residual disease positive status was associated with lower disease-free survival (hazard ratio 3.4, P=0.005) and lower overall survival (hazard ratio 4.2, P<0.001). Multivariate analysis showed that minimal residual disease positive status determined by sequencing was an independent factor associated with risk of death (hazard ratio 4.54, P=0.005) and the only independent factor conferring risk of relapse (hazard ratio 3.76, P=0.012). This sequencing-based method simplifies and standardizes minimal residual disease evaluation, with high applicability in acute myeloid leukemia. It is also an improvement upon flow cytometry- and quantitative polymerase chain reaction-based prediction of outcomes of patients with acute myeloid leukemia and could be incorporated in clinical settings and clinical trials.